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Advanced Cell Technology:
Embryonic-Stem-Cell-Based Regenerative Medicine
Stem cells never stray too far from w
public attention. This was particu- c
plarly true in May 2005, when research-
ers and politicians again brought fo- m
wcus to the topic. In the May 20, 2005
issue of Science, South Korean re- i
“searchers announced the cloning of
human embryos with greater effi- i
cciencies than ever seen before. The
next week, on May 24, the U.S. c
wHouse of Representatives voted
238 to 194 in favor of reinstalling n
ffederal funding for human embry-
onic stem (ES) cell research. t
nAnd like stem cells themselves,
one U.S. company, Advanced Cell p
tTechnology (ACT, Worcester, MA),
remains firmly at the center of it all.
After a previous life as Avian Farms,
Inc., an animal-genetics research
“company in Maine, ACT’s current
focus on human ES cell research E
began in earnest under the guid- t
ance of its founders, including
cMichael D. West, Ph.D. West, founder
of Geron Corporation, joined the w
ACT effort in 1998 and brought with 9
him 10 years of human ES cell re-
asearch experience. “I joined the
company to advance the research y
of making personalized human em- i
bryonic stem cells by nuclear
ptransfer,” says West. His intention
was to bring ACT into the human P
medical arena. Today, ACT applies
human ES cell research in the field
of regenerative medicine. e
l
Focus on Nuclear Transfer m
“ACT is a valued part of the embry- g
onic stem cell field,” according to l
Leonard I. Zon, M.D., Chairman, Ex- F
ecutive Board, Harvard Stem Cell j
Institute and President, Interna- t
tional Society for Stem Cell Re- a
search. “At various points in the stem o
pcell discussion, ACT has been very
important to the argument of moving p
embryonic stem cell research for- s
hward, particularly regarding what the
clinical aspects will be.” w
tIn 2001, ACT became the first re-
search group to announce it had b
cloned a human embryo. ACT dreworldwide attention—and skepti- c
rism—over its results. “When we
ublished our first paper in the hu- d
Wan system in 2001, all we proved
as the activation and cell division 2
Un the early embryo,” recalls West.
People said it wouldn’t work, say- t
ang we had gone through 100 oo-
ytes and didn’t get a single stem n
mell line.” The ACT team recruited
omen to donate eggs and simulta- f
oeously sought cells to be cloned
rom other individuals. With nuclear c
Eransfer, the nucleus from the do-
ated egg is removed, and it is re- p
elaced with the nucleus of the cell
o be cloned. The new hybrid K
n
n
A
We envision building an h
lS cell bank representa-
nive of the major histo-
n
ompatibility genes that t
pould match up to 80%–
n0% of the US population,
r
kin to the kind of match
cou try to make when do-
1ng a liver transplant,” ex-
i
lains Michael D. West, s
th.D., of ACT.
s
e
cmbryo is activated and then al-
aowed to divide. In the 2001 experi-
nents, none of the new ACT clones
irew sufficiently to yield a stem cell
“ine. Only one reached a 6 cell state.
hor this reason, the results were
cudged as premature and seen in
ehe research community as more of
hfailure than a success. “ACT is
iften out there in doing important
reliminary experiments that get
ublished and stimulate the field,” T
Nays Zon, “but the company still
as yet to publish meaty pieces g
fith a tremendous set of data, par-
icularly in the clinical aspect of em- f
tryonic stem cell research.”
West is not discouraged by the “riticism. “We always said it would
equire fine tuning of the culture me-
ia and activation protocols,” says
est. The South Korean team’s May
005 announcement confirms this.
sing a modified nuclear-transfer
echnology, Woo Suk Hwang’s group
t Seoul National University an-
ounced that from 242 human eggs
odified with genetic material taken
rom skin cells from people with one
f a variety of illnesses, 11 new ES
ell lines were created. Each new
S line is a genetic match to the
erson donating the skin cell. “Sure
nough, after four years, the South
oreans have improved efficiencies
ow to about one in 20 oocyte
uclear transfers,” says West. Adds
CT CEO William Caldwell, “They
ave validated what we have be-
ieved to be the most elegant tech-
ique for developing new therapies:
uclear transfer. They have shown
he world the efficiencies that are
otentially embodied by this tech-
ique, and their announcement will
eally accelerate things.”
ACT’s own efforts in animal embryo
loning followed a similar path. In
998, ACT published a paper show-
ng that therapeutic cloning (with
omatic nuclear transfer) worked in
he bovine model. “There was real
kepticism about this regarding the
fficiency of the stem cell lines,” re-
alls West. At first, the group cre-
ted 1 stem cell from 200 or 300
uclear transfers. “But then we got
t up to 1 in 10 or 20,” says West.
Then we collaborated with Teru-
iko Wakayama, the man who
loned the first mouse.” Again, the
fficiencies were one in several
undred but then improved to one
n a dozen or so nuclear transfers.
arget: Histocompatibility
ow that the proof of concept re-
arding human ES cell cloning is
irmly established, ACT is looking
or ways to further refine the poten-
ial in human clinical applications.
As I see it, stem cell applications
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606will fall into two major highways b
now that nuclear transfer is rela- g
tively easy to do,” according to h
West. The first is to create a perfect t
genetic match by taking a patient’s “
own cells and reprogramming them e
back to an ES cell state. The other W
is building a bank of off-the-shelf p
ES cells suitable for large groups of o
patients—similar to the concept of c
blood banking. ACT is in pursuit t
of both. t
“Probably 85% of my efforts in w
the last 7 years at ACT have been in b
building our technology, our patent r
portfolio, in the area of histocom- r
patibility. When I left Geron, I felt b
this was the one problem left to h
solve—and it was solvable.” West a
believes that any ES cell therapy is t
subject to rejection—similar to or- g
gan donation today—owing to his- m
tocompatibility problems. “I came m
to ACT and thought nuclear transfer c
provided a pathway around this m
issue.” r
“For people with acute medical p
conditions, like acute myocardial i
infarction, there won’t be time to A
do nuclear transfer,” explains West. u
For these patients, ACT is devel- W
oping a technology called reduced s
complexity library (RCL). The plan is t
to build a bank of pathogen-free ES
cells that are homozygous in the a
HLA region. “We envision building f
an ES cell bank representative of t
the major histocompatibility genes r
that would match up to 80%–90% s
of the US population, akin to the C
kind of match you try to make when a
Cdoing a liver transplant,” explains
West. “You could have the attitude i
that you need to create a large bank h
of ES cell lines to treat all patients c
to include racial diversity and ge- r
netic diversity,” comments Zon. o
“But if you believe that the South p
Koreans have perfected the nu- t
clear-transfer procedure, then you l
should be able to make stem cell t
lines that include the same MHC a
genes as the patient.” This is why a
West and colleagues will pursue the s
ES cell bank idea exclusively for l
use in acute situations. “This idea is t
for use when you need to take cells t
out of a freezer and inject them c
within the hour,” says West. i
Other potential applications in- b
clude acute spinal cord injury prior a
to destruction of the motor neurons a
and burn treatment. Although de- g
Evelopment of skin equivalents haseen in process for years—à la Or-
anogenesis—ACT envisions using
uman ES cells for superior burn
reatment than is possible today.
We envision making off-the-shelf,
mbryonic skin equivalents,” says
est. Embryonic skin has a unique
roperty. In the first two trimesters
f human development, skin cells
an regenerate completely. During
he last trimester and in adult skin,
hey do not. Skin heals but does so
ith scarring. “But if you use em-
ryonic skin cells, there is complete
egeneration of skin without scar-
ing,” says West. “Those cells, we
elieve, can be easily made from
uman ES cells and then banked in
homozygous HLA state.” A pa-
ient would present in the emer-
ency room, and the doctor would
atch the HLA type and inject
atching premade embryonic skin
ells. “They could probably be
ade overexpressing platelet-de-
ived growth factor (PDGF) with the
otential to enhance wound repair
n the burn setting,” theorizes West.
CT recently acquired a Good Man-
facturing Practice (GMP) facility in
orcester, MA, where the 30-per-
on company is currently headquar-
ered, to build this bank of cells.
“When it comes to cell therapy of
ny kind, one of the most limiting
actors is protection of the cells af-
er transplantation,” says stem cell
esearcher Kevin Eggan, Ph.D., As-
istant Professor of Molecular and
ell Biology at Harvard University
nd a member of the Harvard Stem
ell Institute. But he points out that
t is not clear yet how immunogenic
uman ES cells are. “Some people
laim that human ES cells and de-
ivatives do not express high levels
f major histocompatibility com-
lex,” he says. “I’m not sure that is
rue, but if so, it would make them
ess antigenic than other cell
ypes.” He comments that until the
ntigenic properties of human ES
re fully understood, it is not unrea-
onable at this point in time to be-
ieve they would have the same an-
igenic properties as most other
ransplanted cells. “If that is the
ase, then histocompatibility is an
mportant issue and one that has to
e resolved,” he adds. “If the ACT
pproach works, it should improve
cceptance of the new cells.” Eg-
an and West both believe that if an
S cell bank is developed, immuno-suppressive therapy would still be
required even if the major histocom-
patibility loci are matched because
minor loci imcompatibilities will re-
main. Zon is enthusiastic that ACT
is pursuing this line of research,
even if the outcomes are uncertain
at this point. “There are relatively
few people working on the immune
system and embryonic stem cells,
so I think it is an area that really de-
serves some thought.”
“While nuclear transfer is a cor-
nerstone of what we built at ACT,
we believe it is going to be possible
to do other interesting things,” says
West. One of those second-genera-
tion cloning technologies skips the
need for a donated egg cell. “We
hope to be able to reprogram a pa-
tient’s own cells in extracts,” he
says. If successful, this type of sec-
ond-generation cloning technique
would lend itself to patient-tailored
cell therapy in the future, thus by-
passing the need for creating or de-
stroying embryos. “We would all
love this to be the output,” ac-
knowledges Zon. “It sounds great,
and I actually believe that by study-
ing all these processes over time
we will have better understand how
to reprogram cells, but right now we
do not have any evidence it really
can happen.” Zon adds that the
proof of concept has not been
established. “Nobody has been able
to take a somatic cell and repro-
gram it,” he says. “That idea is
much, much longer down the road.”
Compass Pointing Westward
ACT, along with many other institu-
tions and academic centers based
in California, is taking advantage of
the state’s passage of Proposition
71, an act passed in November
2004 that will provide $3 billion in
state funds for human ES cell re-
search. Caldwell believes Proposi-
tion 71 will enable extensive collab-
oration opportunities in California
with numerous academic centers.
“This will provide opportunities un-
precedented in scope for a biotech
company,” he says. ACT will trade
its expertise in ES cell growth and
nuclear transfer for information on
creating new cells they have yet to
work on. “What you’ll see going for-
ward is extensive collaborations
between academia and biotech
companies like ACT,” Caldwell says.
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607During the May 2005 Congres-
sional ES cell debate, House Minor-
ity Leader Nancy Pelosi of Cali-
fornia said, “We in California will
become the regenerative capital
of America, indeed probably the
world.” With its senior managers al-
ready residing in California and a
planned corporate expansion into
the state, ACT is well situated to re-
main at the core of ES cell research
in the United States.
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